E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Antivirals"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 July 2011)

Special Issue Editor

Guest Editor
Prof. Dr. Ulrich Jordis (Website)

Institute of Applied Synthetic Chemistry, Vienna University of Technology, Getreidemarkt 9/163, A-1060 Wien, Austria
Fax: +43 1 58801 15499
Interests: antivirals; Alzheimer; quinolones; combinatorial chemistry; labelled compounds; natural products (alkaloids; triterpenes); custom synthesis; chemistry software and databases

Special Issue Information

Dear Colleagues,

Molecules and Pharmaceuticals, being pioneer journals of web-based publications, invites you to submit research articles and comprehensive reviews addressing the discovery and/or development of antiviral agents in animals and man as well as in plants or lower organisms. Despite the tremendous successes and hallmarks e.g. in treating AIDS, clearly there is an ongoing and increased challenge to cope with the evolutionary and constantly changing threats of viral infections that have even the potential to ultra-risks for the mankind. Natural products continue to provide important leads and structures for the development of antiviral compounds and insights into the biochemical pathways and cell live cycles provide new starting points for new antiviral mechanisms. This issue intends to delineate the efforts being made to develop new and effective broad-spectrum antiviral agents e.g. for the treatment of HSV, VZV, HIV, HBV and DNA virus infections.

Prof. Dr. Ulrich Jordis
Guest Editor

Related Special Issue

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments
Pharmaceuticals 2011, 4(12), 1518-1534; doi:10.3390/ph4121518
Received: 31 August 2011 / Revised: 16 November 2011 / Accepted: 18 November 2011 / Published: 25 November 2011
Cited by 6 | PDF Full-text (3893 KB) | HTML Full-text | XML Full-text
Abstract
Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in [...] Read more.
Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in serious cases influenza A leads to pneumonia, which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and the elderly. In the present study, we show a protective effect of the low-molecular weight compound Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxohexanoic acid) against influenza A (H1N1) virus, human parainfluenza virus and human adenovirus infections in animals. Mortality, weight loss, infectious titer of the virus in tissues and tissue morphology were monitored in the experimental groups of animals. The protective action of Ingavirin was observed as a reduction of infectious titer of the virus in the lung tissue, prolongation of the life of the infected animals, normalization of weight dynamics throughout the course of the disease, lowering of mortality of treated animals compared to a placebo control and normalization of tissue structure. In case of influenza virus infection, the protective activity of Ingavirin was similar to that of the reference compound Tamiflu. Based on the results obtained, Ingavirin should be considered as an important part of anti-viral prophylaxis and therapy. Full article
(This article belongs to the Special Issue Antivirals)

Review

Jump to: Research

Open AccessReview Echinacea—A Source of Potent Antivirals for Respiratory Virus Infections
Pharmaceuticals 2011, 4(7), 1019-1031; doi:10.3390/ph4071019
Received: 8 June 2011 / Revised: 30 June 2011 / Accepted: 7 July 2011 / Published: 13 July 2011
Cited by 8 | PDF Full-text (67 KB) | HTML Full-text | XML Full-text
Abstract
Extracts of Echinacea species have been used traditionally in North America for the control of symptoms of colds, influenza, and other diseases, and some of them have become very popular as “herbal medicines”. Recent studies have revealed that preparations derived from certain [...] Read more.
Extracts of Echinacea species have been used traditionally in North America for the control of symptoms of colds, influenza, and other diseases, and some of them have become very popular as “herbal medicines”. Recent studies have revealed that preparations derived from certain species and plant parts, but not all of them, possess potent antiviral activities, at non-cytotoxic concentrations, particularly against membrane-containing viruses. Thus all strains of human and avian influenza viruses tested (including a Tamiflu-resistant strain), as well as herpes simplex virus, respiratory syncytial virus, and rhinoviruses, were very sensitive to a standardized Echinacea purpurea preparation. In mechanistic studies the influenza virus-specific hemagglutinin and neuraminidase were inhibited. In addition some extracts displayed anti-inflammatory activity in virus-infected cells, and numerous other effects on the expression of cellular genes. Multiple components, either discrete compounds or mixtures, appeared to be responsible for the various antiviral activities. Full article
(This article belongs to the Special Issue Antivirals)
Open AccessReview Anti-Viral Drugs for Human Adenoviruses
Pharmaceuticals 2010, 3(10), 3343-3354; doi:10.3390/ph3103343
Received: 2 September 2010 / Revised: 23 October 2010 / Accepted: 25 October 2010 / Published: 25 October 2010
Cited by 6 | PDF Full-text (607 KB) | HTML Full-text | XML Full-text
Abstract
There are many stages in the development of a new drug for viral infection and such processes are even further complicated for adenovirus by the fact that there are at least 51 serotypes, forming six distinct groups (A–F), with different degree of [...] Read more.
There are many stages in the development of a new drug for viral infection and such processes are even further complicated for adenovirus by the fact that there are at least 51 serotypes, forming six distinct groups (A–F), with different degree of infectivity. This review attempts to address the importance of developing pharmaceuticals for adenovirus and also review recent development in drug discovery for adenovirus, including newer strategies such as microRNA approaches. Different drug screening strategies will also be discussed. Full article
(This article belongs to the Special Issue Antivirals)

Journal Contact

MDPI AG
Pharmaceuticals Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceuticals@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceuticals
Back to Top